Early-Stage Human Data

We share results from an early human study, where selected biomarkers were measured before and after short-term supplementation. Changes were observed in markers such as p21 and IL-6. These results are considered preliminary and are currently under peer review. The purpose of sharing is transparency, not to suggest medical conclusions. More research, including larger and controlled studies, will be needed to confirm these findings.

View Research Data
Senolytic comparison

Start Your Senotherapeutic Protocol

Frequently Asked Questions

Is it safe?

Initial human references report no adverse effects; larger and independent studies are needed. Individualize and consult a professional when appropriate.

How fast could I notice anything?

Reports mention sleep/energy changes within days in some contexts; responses vary widely. Log a baseline and re measure on schedule.

How is this different from D+Q, fisetin, or quercetin?

Emphasis on a dose-dependent dual mechanism plus a phospholipid complex for absorption; model data show higher peak clearance vs common alternatives. Context and limits apply—see Comparisons.

For Cellular Senescence Research